AstraZeneca today announced that the Marketing Authorisation Application for CAPRELSA (vandetanib) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. The proposed indication also states that for patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit
LIV-24 applies ESG Tech AI technology, revolutionising industrial sector Cuts costs, increases productivity, facilitates sustainable business
—
At present,...
TAT and International Partners Urge Thai Businesses to Prepare for Imminent EU Regulations on Sustainable Tourism
—
On September 26, at the Avani+ Riversi...
International efforts to protect and empower ASEAN's women migrant workers
—
International organisations under the United Nations (UN) and the European Un...
EXPORT PROMOTION SEMINAR TO HIGHLIGHT EXCELLENCE OF EUROPEAN FOOD
—
H.E. Mr. David Daly, Ambassador of the European Union to Thai (EU) is set to host a tw...
Vaxzevria approved in the EU as third dose booster against COVID-19
—
Approval follows CHMP recommendation for use in patients previously vaccinated with ...
'EU Sustainable Food & Craft Market' champions sustainable SMEs to mark Europe Day
—
To celebrate Europe Day 2022, the Delegation of the European Unio...
TH-EU: The Phuket Youth's Awareness Raising for Separate Collection
—
Today, the Prince of Songkhla University, Phuket Campus was the hub to learn and exc...
BLUE ELEPHANT GROUP'S STEPPE FAMILY MEETS AMBASSADOR OF THAILAND TO BELGIUM
—
H.E. Mr. Sek Wannamethee (2nd from left), Head of the Thai delegation to the...